Covid-19 Treatment Developer Humanigen Files for Bankruptcy
California-based company says FDA’s rejection of lenzilumab is a major cause of its financial troubles. Continue reading
0.0001 | |
0.0001 | |
7368 | |
0.0001 | |
0.0001 | |
0 - 0 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
California-based company says FDA’s rejection of lenzilumab is a major cause of its financial troubles. Continue reading
The RATinG (Risk Adapted Therapy in Acute GvHD) is the first trial to explore granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralization for the early treatment of participants with high-risk acute Graft versus Host Disease Planned interim assessment expected in 2024 following treatmen...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: